What is the recommended management for nasal polyps?

Management of Nasal Polyps

Intranasal corticosteroids are the cornerstone of medical management for nasal polyps, with twice-daily dosing superior to once-daily, and should be continued long-term as maintenance therapy. 1

First-Line Medical Management

Intranasal Corticosteroids (Primary Treatment)

• Intranasal corticosteroids significantly improve sense of smell, reduce nasal congestion, and decrease polyp size compared to placebo, with effects optimized by twice-daily versus once-daily dosing 1

• Multiple delivery methods are available: nasal sprays, irrigations/rinses, drops, exhalation delivery systems, and corticosteroid-eluting stents 1

• Nasal corticosteroid irrigations (e.g., budesonide 1000μg or mometasone 2000μg in 240ml saline) demonstrate superior efficacy compared to nasal sprays for endoscopic scores and symptom control in postoperative patients 1

• Meta-analysis shows nasal corticosteroids significantly improve disease-specific quality of life (SNOT-22) with mean difference of -5.46 (95% CI -8.08 to -2.84) 1

• Corticosteroid-eluting sinus implants placed in the ethmoid reduce nasal obstruction, polyp grade, and need for surgery (OR 0.37,95% CI 0.23-0.61) at 90 days, though the effect size is modest 1

Short-Course Systemic Corticosteroids

• For severe nasal polyposis, a short course of oral prednisone (25-60mg for 7-20 days) is highly effective in reducing symptoms and polyp size, with significant improvement in total symptom score (SMD -1.51,95% CI -1.08 to -1.57) at 2-4 weeks 1

• Beneficial effects must be maintained by subsequent administration of intranasal corticosteroids 1

• The effect diminishes by 10-12 weeks after treatment initiation, emphasizing the need for maintenance therapy 1

Second-Line Medical Therapies

Leukotriene Modifiers (Adjunctive)

• Leukotriene modifiers (montelukast, zafirlukast, zileuton) provide subjective improvement as add-on therapy to intranasal corticosteroids but are inferior to intranasal corticosteroids as monotherapy 1

• After sphenoidal ethmoidectomy, montelukast shows equivalent recurrence rates and rescue medication requirements compared to postoperative nasal beclomethasone 1

Aspirin Therapy After Desensitization (AERD Only)

• In patients with aspirin-exacerbated respiratory disease (AERD) and nasal polyps, aspirin desensitization followed by long-term daily aspirin treatment (≥300mg daily) may reduce nasal symptoms, frequency of sinus infections, requirement for polypectomies, and need for systemic corticosteroids 1

• This is a conditional recommendation specific to the AERD subpopulation 1, 2

Biologic Therapies (Severe/Refractory Disease)

Biologics are recommended for severe chronic rhinosinusitis with nasal polyps when consensus-determined criteria are met and patients have failed maximum medical therapy or are unable to undergo surgery. 1, 3

Currently Approved Biologics

• Dupilumab (anti-IL-4Rα) demonstrates the most consistent benefits, leading in SNOT-22 improvement and showing significant improvement in olfactory function (UPSIT scores) 3, 4

• Mepolizumab (anti-IL-5) and omalizumab (anti-IgE) are approved options, particularly beneficial in patients with concomitant poorly controlled asthma 1, 3, 5

• All biologics significantly reduce nasal polyp scores with comparable safety profiles to placebo 3, 4

• Treatment response should be assessed at 6 months; in poor responders, consider alternative biologics or revision surgery 6

Surgical Management

Indications for Surgery

• Functional endoscopic sinus surgery (ESS) is indicated when polyps cause severe obstruction, recurrent sinusitis, or when medical therapy has failed 1, 7

• Patients with advanced disease features (nasal polyps, osteitis, allergic fungal disease) benefit from comprehensive sinus surgery with wide sinus openings to facilitate drainage and topical therapy delivery 1

Surgery Considerations

• Simple polypectomy alone has a 75% recurrence rate at 8-year follow-up, making comprehensive ESS preferable 1

• Patients with AERD and nasal polyps have worse surgical outcomes than aspirin-tolerant patients 1

• Major complications (CSF leak, hemorrhage requiring transfusion, orbital injury) occur in approximately 1% of cases 1

• Postoperative intranasal corticosteroids significantly prevent polyp recurrence (RR 0.73,95% CI 0.56-0.94) 1

Treatment Algorithm

1. Initiate intranasal corticosteroids twice daily (spray or irrigation depending on disease extent and prior surgery) 1

2. For severe symptoms, add short-course oral corticosteroids (7-20 days), then maintain with intranasal corticosteroids 1

3. Consider leukotriene modifiers as adjunctive therapy if inadequate response 1, 5

4. For AERD patients specifically, consider aspirin desensitization followed by daily aspirin ≥300mg 1

5. If medical therapy fails or severe obstruction persists, proceed to functional endoscopic sinus surgery 1, 7

6. For severe disease refractory to medical and surgical therapy, initiate biologic therapy (dupilumab first-line based on efficacy data) 1, 3, 4

7. Continue long-term maintenance intranasal corticosteroids regardless of treatment pathway 1

Common Pitfalls

• Discontinuing intranasal corticosteroids after symptom improvement leads to recurrence; maintenance therapy is essential 1

• Using once-daily instead of twice-daily intranasal corticosteroid dosing reduces efficacy 1

• Performing simple polypectomy without comprehensive ESS results in high recurrence rates 1

• Failing to recognize AERD as a distinct entity that benefits from aspirin desensitization 1

• Not considering biologics in appropriate candidates with severe refractory disease 3, 6